{"id":"bf-200-ala-10","safety":{"commonSideEffects":[{"rate":null,"effect":"Erythema"},{"rate":null,"effect":"Edema"},{"rate":null,"effect":"Burning/pain at application site"},{"rate":null,"effect":"Photosensitivity"},{"rate":null,"effect":"Crusting/scaling"}]},"_chembl":{"chemblId":"CHEMBL3781418","moleculeType":"Protein","molecularWeight":"3638.56"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"BF-200 ALA is a photodynamic therapy (PDT) agent that penetrates skin tissue and is converted to protoporphyrin IX, a photosensitizer. Upon illumination with red light, protoporphyrin IX generates singlet oxygen and reactive oxygen species that induce apoptosis and necrosis in target cells, particularly actinic keratosis and other precancerous lesions.","oneSentence":"BF-200 ALA is a topical 5-aminolevulinic acid (ALA) formulation that generates reactive oxygen species upon light activation to destroy abnormal skin cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:23:24.342Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Actinic keratosis (field treatment)"},{"name":"Non-melanoma skin cancer precursor lesions"}]},"trialDetails":[{"nctId":"NCT06665724","phase":"PHASE1","title":"Clinical Trial Evaluating Safety of 5-Aminolevulinic Acid (5-ALA) Combined With CV01 Delivery of Ultrasound for Sonodynamic Therapy (SDT) in Patients With Newly Diagnosed High-Grade Glioma (HGG) Prior to Resection and Standard Adjuvant Therapy (ALA SDT GLIOMA 401)","status":"COMPLETED","sponsor":"Universität Münster","startDate":"2025-01-27","conditions":"Anaplastic Astrocytoma (AA), Anaplastic Oligodendroglioma (AO), Glioblastoma (GBM)","enrollment":16},{"nctId":"NCT06307548","phase":"PHASE1, PHASE2","title":"Fluorescence Image Guided Surgery Followed by Intraoperative Photodynamic Therapy for Improving Local Tumor Control in Patients With Locally Advanced or Recurrent Colorectal Cancer","status":"SUSPENDED","sponsor":"Roswell Park Cancer Institute","startDate":"2024-07-30","conditions":"Locally Advanced Colorectal Carcinoma, Recurrent Colorectal Carcinoma, Stage III Colorectal Cancer","enrollment":21},{"nctId":"NCT03573401","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT).","status":"ACTIVE_NOT_RECRUITING","sponsor":"Biofrontera Inc.","startDate":"2018-09-25","conditions":"Superficial Basal Cell Carcinoma","enrollment":187},{"nctId":"NCT07075328","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of OJP-001 in Patients With Adult T-cell Leukemia/Lymphoma","status":"RECRUITING","sponsor":"Otsuka Medical Devices Co., Ltd. Japan","startDate":"2024-04-01","conditions":"Adult T-Cell Leukemia/Lymphoma (ATLL)","enrollment":49},{"nctId":"NCT06027619","phase":"PHASE2","title":"Short Contact Protocols to Reduce Pain During 10% ALA Gel Red-light Photodynamic Therapy of Actinic Keratoses","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2023-10-02","conditions":"Actinic Keratosis","enrollment":30},{"nctId":"NCT04400539","phase":"PHASE2","title":"The IMmunotherapy Pleural 5-ALA PDT","status":"RECRUITING","sponsor":"University Hospital, Lille","startDate":"2022-05-09","conditions":"Mesotheliomas Pleural, Malignant Pleural Mesothelioma","enrollment":20},{"nctId":"NCT06159842","phase":"PHASE2","title":"Evaluating the Use of Photodynamic Therapy to Treat Facial Cutaneous Squamous Cell Carcinoma in Situ (isSCC)","status":"COMPLETED","sponsor":"The Center for Clinical and Cosmetic Research","startDate":"2023-08-08","conditions":"Facial Cutaneous Squamous Cell Carcinoma in Situ","enrollment":32},{"nctId":"NCT06745999","phase":"PHASE4","title":"Cryotherapy in Combination with Red Light PDT for Actinic Keratosis of Full Face","status":"RECRUITING","sponsor":"Psoriasis Treatment Center of Central New Jersey","startDate":"2023-05-03","conditions":"Actinic Keratoses","enrollment":40},{"nctId":"NCT05123534","phase":"PHASE2","title":"A Phase 2 Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Patients with DIPG","status":"SUSPENDED","sponsor":"SonALAsense, Inc.","startDate":"2022-08-12","conditions":"Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma","enrollment":15},{"nctId":"NCT05370508","phase":"PHASE1, PHASE2","title":"A Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Subjects With Recurrent GBM","status":"TERMINATED","sponsor":"SonALAsense, Inc.","startDate":"2023-02-06","conditions":"Recurrent GBM","enrollment":8},{"nctId":"NCT06418113","phase":"PHASE1","title":"Neoadjuvant Radio-chemotherapy Safety Pilot Study in Patients With Glioblastoma","status":"RECRUITING","sponsor":"Hospital San Carlos, Madrid","startDate":"2024-03-21","conditions":"Glioblastoma, Glioblastoma Multiforme, Glioblastoma, IDH-wildtype","enrollment":12},{"nctId":"NCT05522036","phase":"NA","title":"Clinical Evaluation of a Short Illumination Duration (35 Minutes) When Performing PDT of AK Using the Dermaris ®","status":"COMPLETED","sponsor":"Centre Dermatologique du Roy","startDate":"2022-01-01","conditions":"Actinic Keratoses","enrollment":25},{"nctId":"NCT01966120","phase":"PHASE3","title":"Safety and Efficacy Study for the Field-directed Treatment of Actinic Keratosis (AK) With Photodynamic Therapy (PDT)","status":"COMPLETED","sponsor":"Biofrontera Bioscience GmbH","startDate":"2013-10","conditions":"Actinic Keratosis","enrollment":87},{"nctId":"NCT03109353","phase":"PHASE1, PHASE2","title":"Modification of Extracorporeal Photopheresis in Cutaneous T-cell Lymphoma or Chronic Graft-versus-host Disease","status":"COMPLETED","sponsor":"St. Olavs Hospital","startDate":"2017-09-20","conditions":"Cutaneous T-Cell Lymphoma, Unspecified, Chronic Graft Versus Host Disease in Skin","enrollment":7},{"nctId":"NCT05359419","phase":"PHASE4","title":"Comparison of Two Modes of Photodynamic Therapy for the Treatment of Actinic Keratosis on the Upper Extremities","status":"UNKNOWN","sponsor":"Goldman, Butterwick, Fitzpatrick and Groff","startDate":"2022-05-15","conditions":"Skin Neoplasms","enrollment":20},{"nctId":"NCT04044898","phase":"PHASE1","title":"Pharmacokinetics and Safety of ALA in Acne Vulgaris","status":"COMPLETED","sponsor":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.","startDate":"2021-01-12","conditions":"Acne Vulgaris","enrollment":19},{"nctId":"NCT05228483","phase":"NA","title":"Carbon Dioxide（CO2）Fractional Laser Plus Photodynamic Therapy in Female Patients With Vulvar Lichen Sclerosus","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2021-11-23","conditions":"Vulva Lichen Sclerosus","enrollment":134},{"nctId":"NCT04319159","phase":"PHASE1","title":"Study to Evaluate the Safety of BF-200 ALA (Ameluz®) for Photodynamic Therapy (PDT) in the Treatment of Expanded Fields of Actinic Keratosis (AK)","status":"COMPLETED","sponsor":"Biofrontera Bioscience GmbH","startDate":"2020-03-05","conditions":"Actinic Keratoses","enrollment":48},{"nctId":"NCT04018885","phase":"PHASE1, PHASE2","title":"A Study on Safety and Preliminary Efficacy of ALA in Acne Vulgaris","status":"COMPLETED","sponsor":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.","startDate":"2019-07-11","conditions":"Acne Vulgaris","enrollment":72},{"nctId":"NCT03596619","phase":"NA","title":"The Study of Plum-blossom Needling Enhancing Efficacy of Aminolevulinic Acid-photodynamic Therapy for Actinic Keratosis","status":"UNKNOWN","sponsor":"Shanghai Dermatology Hospital","startDate":"2018-08-30","conditions":"Actinic Keratoses","enrollment":250},{"nctId":"NCT03642535","phase":"PHASE4","title":"Aminolevulinic Acid-photodynamic Therapy for Facial Actinic Keratosis Treatment and Prevention","status":"UNKNOWN","sponsor":"Shanghai Dermatology Hospital","startDate":"2018-08-30","conditions":"Actinic Keratoses","enrollment":300},{"nctId":"NCT02239679","phase":"PHASE2","title":"Controlled Study of the Occurrence of Actinic Keratosis on the Face After Cryotherapy + Aminolevulinic Acid (ALA) Photodynamic Therapy","status":"COMPLETED","sponsor":"DUSA Pharmaceuticals, Inc.","startDate":"2014-09","conditions":"Actinic Keratosis","enrollment":166},{"nctId":"NCT02632110","phase":"PHASE2","title":"Microneedle Lesion Preparation Prior to Aminolevulinic Acid Photodynamic Therapy (ALA-PDT) for AK on Face","status":"COMPLETED","sponsor":"DUSA Pharmaceuticals, Inc.","startDate":"2016-03","conditions":"Actinic Keratosis","enrollment":137},{"nctId":"NCT03024060","phase":"PHASE3","title":"Phase 3 Study of Levulan With New Blue Light for AK on the Face or Scalp","status":"WITHDRAWN","sponsor":"DUSA Pharmaceuticals, Inc.","startDate":"2017-03","conditions":"Actinic Keratosis","enrollment":""},{"nctId":"NCT02628236","phase":"PHASE2","title":"Maximal Use Systemic Exposure Study of Levulan Kerastick (MUSE 2)","status":"COMPLETED","sponsor":"DUSA Pharmaceuticals, Inc.","startDate":"2016-02","conditions":"Keratosis, Actinic","enrollment":14},{"nctId":"NCT02281136","phase":"PHASE2","title":"Maximal Use Systemic Exposure (MUSE) Study of Levulan Kerastick","status":"COMPLETED","sponsor":"DUSA Pharmaceuticals, Inc.","startDate":"2014-12","conditions":"Keratosis, Actinic","enrollment":29},{"nctId":"NCT02119338","phase":"NA","title":"5-ALA in Recurrent Glioma","status":"UNKNOWN","sponsor":"St. Joseph's Hospital and Medical Center, Phoenix","startDate":"2014-02","conditions":"Glioma","enrollment":60},{"nctId":"NCT01475955","phase":"PHASE2","title":"Short-incubation Levulan Photodynamic Therapy Versus Vehicle for Face/Scalp Actinic Keratosis (AK)","status":"COMPLETED","sponsor":"DUSA Pharmaceuticals, Inc.","startDate":"2011-12","conditions":"Actinic Keratosis","enrollment":235},{"nctId":"NCT02799030","phase":"PHASE2","title":"A Clinical Trial of Topical Photodynamic Therapy With 5-aminolevulinic Acid for the Treatment of Actinic Keratosis","status":"COMPLETED","sponsor":"Biofrontera Bioscience GmbH","startDate":"2006-10","conditions":"Actinic Keratosis","enrollment":105},{"nctId":"NCT02137785","phase":"PHASE3","title":"Safety and Efficacy Study of Photodynamic Therapy With Levulan Kerastick + Blue Light for Actinic Keratoses on the Upper Extremities","status":"COMPLETED","sponsor":"DUSA Pharmaceuticals, Inc.","startDate":"2014-05","conditions":"Actinic Keratosis","enrollment":269},{"nctId":"NCT01458587","phase":"PHASE2","title":"Levulan PDT Versus Vehicle for Extremity Actinic Keratoses (AK)","status":"COMPLETED","sponsor":"DUSA Pharmaceuticals, Inc.","startDate":"2011-11","conditions":"Keratosis, Actinic","enrollment":70},{"nctId":"NCT01697670","phase":"PHASE1","title":"Photodynamic Therapy for Ulcerative Colitis","status":"UNKNOWN","sponsor":"University of Zurich","startDate":"2012-09","conditions":"Ulcerative Colitis","enrollment":7},{"nctId":"NCT00865878","phase":"PHASE2","title":"ALA-PDT Versus Vehicle PDT for Treatment of AK and Reduction of New NMSC in Solid Organ Transplant Recipients","status":"TERMINATED","sponsor":"DUSA Pharmaceuticals, Inc.","startDate":"2009-05","conditions":"Actinic Keratoses, Skin Neoplasms","enrollment":6}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ameluz"],"phase":"phase_2","status":"active","brandName":"BF-200 ALA 10%","genericName":"BF-200 ALA 10%","companyName":"Biofrontera Bioscience GmbH","companyId":"biofrontera-bioscience-gmbh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BF-200 ALA 10% is used in aminolevulinic acid-photodynamic therapy for treating and preventing facial actinic keratosis. This treatment involves applying BF-200 ALA 10% followed by exposure to a light source, such as BLU-U.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2016-05-10T00:00:00.000Z","mah":"BIOFRONTERA","brand_name_local":"AMELUZ","application_number":"NDA208081"}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}